Clicky

Omega Therapeutics, Inc.(OMGA)

Description: Omega Therapeutics, Inc., a biotechnology company, develops genomic medicines to cure diseases. The company focuses on precision tuning to activate the human genome's native capacity to treat and cure diseases. It engages in designing, engineering, and manufacturing Epigenomic Controllers to target the GenomStats for the cell types of interest, with the ability to downregulate or upregulate genomic activity for therapeutic effect. Omega Therapeutics, Inc. was formerly known as VL42, Inc. and changed its name to Omega Therapeutics, Inc. in July 2017. The company was incorporated in 2016 and is based in Cambridge, Massachusetts.


Keywords: Biotechnology Disease Human Genome

Home Page: omegatherapeutics.com

OMGA Technical Analysis

20 Acorn Park Drive
Cambridge, MA 02140
United States
Phone: 617 949 4360


Officers

Name Title
Dr. Noubar B. Afeyan Ph.D. Co-Founder & Chairman
Mr. Mahesh Karande Pres, CEO & Board Director
Dr. Thomas McCauley Chief Scientific Officer
Mr. Joshua Reed M.B.A. Chief Financial Officer
Dr. Sivakesava Sakhamuri Ph.D. Sr. VP and Head of Technical Operations & Quality
Ms. Ling Zeng Esq., J.D. Chief Legal & Admin. Officer and Sec.
Mr. Kevin McManus Chief HR Officer
Ms. Barbara Y. Chan Sr. VP of Fin.
Mr. Charles O'Donnell Ph.D. VP and Head of Computational Genomics & Data Sciences
Dr. Yan Moore M.D. Chief Medical Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.2829
Price-to-Sales TTM: 197.7721
IPO Date: 2021-07-30
Fiscal Year End: December
Full Time Employees: 79
Back to stocks